AAV-based GRN gene therapy (Pharmaceutical Product Development)

N/A

Report date: 2025/03/14 16:46:49

Base Information

Drug NameAAV-based GRN gene therapy (Pharmaceutical Product Development)

Drug Alias NameAAV serotype 9 expressing codon-optimized human GRN gene therapy (Pharmaceutical Product Development)AAV-based gene therapy (Pharmaceutical Product Development)

ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector

Mechanisms of ActionProgranulin modulators

TargetsProgranulin

Therapy Area/IndicationsFrontotemporal Dementia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryEurope

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesPharmaceutical Product Development Llc

China Registration ClassN/A

Develop Information

Active CompaniesPharmaceutical Product Development Llc

Inactive CompaniesN/A

Active IndicationsFrontotemporal Dementia

Inactive IndicationsN/A

Other Information

ATC CodeN/A